Exchange: NASDAQ·Updated 09:28 PM EDT
AUTL logo

AUTLAutolus Therapeutics Ltd - ADR

$1.46
$0.065
(4.64%)
Today
Closed $1.47
$0.005
(0.34%)
Overnight
EarningsAug 7
Mkt Cap$389.92M
Vol879,129.00
News
all
press releases
Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees
Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees...
Yahoo! Finance: News
More News
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
Zacks
Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Autolus Therapeutics (AUTL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Zacks
Autolus Therapeutics Q1 Earnings Call Highlights
Autolus Therapeutics Q1 Earnings Call Highlights...
Yahoo! Finance: News
HC Wainwright Has Negative Outlook for AUTL Q2 Earnings
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Stock analysts at HC Wainwright dropped their Q2 2026 earnings estimates for shares of Autolus Therapeutics in a note issued to investors on Thursday, April 30th. HC Wainwright analyst E. Bodnar now anticipates that the company wil...
MarketBeat
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine ratings firms that are covering the company...
MarketBeat
Autolus Therapeutics (NASDAQ:AUTL) Stock Rating Upgraded by Jefferies Financial Group
Jefferies Financial Group raised Autolus Therapeutics to a "strong-buy" rating in a report on Monday...
MarketBeat
Autolus Therapeutics Eyes CAR-T Edge With AUCATZYL Safety, Expands Centers, Sees Margin Turnaround
Autolus Therapeutics (NASDAQ:AUTL) is seeking to differentiate itself in the CAR-T market by pairing strong clinical activity with a safety profile that could allow broader patient access, CEO...
MarketBeat
HC Wainwright Issues Positive Outlook for AUTL Earnings
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Equities research analysts at HC Wainwright lifted their Q1 2026 earnings per share estimates for shares of Autolus Therapeutics...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.